A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover, Single-Centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover, Single-Centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2012

At a glance

  • Drugs AZD 8309 (Primary)
  • Indications Chronic obstructive pulmonary disease; Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Feb 2011 New source identified and integrated (ISRCTN: Current Controlled Trials).
    • 21 Feb 2011 Actual end date changed from Oct 2009 to Dec 2010 as reported by ClinicalTrials.gov.
    • 29 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top